An Expert’s Opinion on Regorafenib

Oncologist Dr Ramesh Balusi on why Regorafenib must be available for Wild Type GIST and it’s incorrect categorisation on the Cancer Drug Fund list.  In reaction to an interview by Sam and Michelle Waller on BBC Radio Sussex.

No comments yet.

Leave a Reply

Built with our compliments, good luck from BN:Coded Ltd